News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Syke Founder Alistair Maiden Joins Legal AI Startup Flank
Alistair Maiden, who built and sold legal engineering firm Syke to Consilio in 2023, has joined Flank as a senior hire. His decade of enterprise legal tech deployment brings credibility to the agent-based automation startup.
Thomson Reuters Integrates DeepJudge Into CoCounsel, Unifies Firm Knowledge
DeepJudge's institutional search now connects to CoCounsel's legal AI, giving lawyers access to firm precedent, Westlaw research, and Practical Law standards in one interface without migrating content.
QC Healthcare Launches Holding Company Spanning Telehealth to AI Analytics
QC Healthcare announced a new holding company structure covering telehealth, clinical research, pharmacy, AI, healthcare analytics, and population health. Details on funding and specific AI capabilities remain unclear.
Eli Lilly Acquires 4E Therapeutics to Build Non-Opioid Chronic Pain Pipeline
Eli Lilly has acquired 4E Therapeutics, a biotech focused on RNA-targeting drugs for chronic pain. The deal advances Lilly's strategy to move away from opioid-based treatments.
Hyperscale Data's $87.1M Bitcoin Treasury Now Worth 73% of Stock Market Cap
Hyperscale Data holds $87.1 million in Bitcoin and cash, representing 73.34% of its current market capitalization. The company's treasury position raises questions about whether the asset base or operating business drives valuation.
GLP-1 drugs reach only 2-3% of Europeans who qualify, despite proven ROI
Obesity medications are delivering real clinical gains and productivity wins across Europe, but healthcare systems are moving too slowly to cover them. Here's why patient stigma and medical training gaps are the actual barriers.
Zai Lab's DLL3 Drug Wins EU Orphan Status for Lung Cancer
Zocilurtatug pelitecan secured EMA orphan drug designation for pulmonary neuroendocrine carcinomas. Three registration studies aim for completion by end of 2026.
Altaris buys Simulations Plus for $375M, merges with molecular design firm
Altaris is acquiring drug-development software maker Simulations Plus for $375M in cash, then combining it with portfolio company Chemical Computing Group to build an integrated biosimulation platform for pharma R&D.
BMS shows 96% response rate for GPRC5D CAR-T in myeloma phase I
Bristol Myers Squibb presented phase I data for arlocabtagene autoleucel targeting GPRC5D, achieving 96% overall response rate in relapsed myeloma patients. But efficacy in BCMA-resistant patients remains unproven.
AviadoBio Expands Gene-Silencing Patent to All Disease Areas
AviadoBio broadened its King's College London licence to deploy vMiX RNAi across cardiovascular, oncology, nephrology, and other fields beyond neurology. The platform silences disease genes with a single dose.
Eight in vivo CAR-T startups to watch in 2026
No approved in vivo CAR-T therapy exists yet, but eight companies from Umoja to Alaya.bio are in preclinical and clinical trials. Here's who is closest to the clinic and why they matter.
Single-Protein Imaging Maps Scramblase Speeds Up to 10,000 Lipids Per Second
Weill Cornell and Ruhr University researchers built a fluorescence microscopy platform to measure individual scramblase activity rates. The technique reveals why some proteins move lipids 100x faster than others.